Human IFABP/FABP2(Intestinal Fatty Acid Binding Protein) ELISA Kit
中文名称：人肠脂肪酸结合蛋白(IFABP/FABP2)酶联免疫吸附测定试剂盒
Price:
- 反应性： Human
- 检测范围： 0.16-10 ng/mL
- 灵敏度： 0.1 ng/mL
| 产品应用 | ELISA |
| 检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗人IFABP/FABP2抗体包被于酶标板上，实验时样品（或标准品）中的人IFABP/FABP2会与包被抗体结合。后依次加入生物素化的抗人IFABP/FABP2抗体和辣根过氧化物酶标记的亲和素，抗人IFABP/FABP2抗体与结合在包被抗体上的人IFABP/FABP2结合，生物素与亲和素特异性结合而形成免疫复合物，游离的成分被洗去。加入显色底物(TMB)，TMB在辣根过氧化物酶的催化下呈现蓝色，加终止液后变成黄色。用酶标仪在450 nm波长处测OD值，IFABP/FABP2浓度与OD450值之间呈正比，通过绘制标准曲线计算出样品中IFABP/FABP2的浓度。 |
| 反应类型 | Sandwich-ELISA |
| 规格 |
96 T
/ 48 T
/ 96 T × 5
|
| 反应时间 | 3 h 30 min |
| 反应性 | Human |
| 检测方法 | 比色法;ELISA;夹心法 |
| 检测范围 | 0.16-10 ng/mL |
| 灵敏度 | 0.1 ng/mL |
| 样本体积 | 100 μL |
| 样本类型 | 血清、血浆或其他生物体液 |
| 特异性 | 可检测样本中的人IFABP/FABP2，且与其它类似物无明显交叉反应 |
| 精密度 | 板内，板间变异系数均<10% |
| 回收率 | 80%-120% |
| 储存条件 | 2-8℃ |
| 有效期 | 12个月 |
| 数据处理 |
-
Heparanase inhibition leads to improvement in patients with acute gastrointestinal injuries induced by sepsis
IF: 4.300 -
CEBPB promotes gastrointestinal motility dysfunction after severe acute pancreatitis via the MALAT1/CIRBP/ERK axis
IF: 3.600 -
Prediction of post-stroke depression with combined blood biomarkers IL-6, TNF-a, and fatty acid binding protein: A prospective study
IF: 2.500Journal： Journal of Medical Biochemistry (2023)Reactivity：HumanSample Type：Blood samples -
Stereotypic Expansion of T Regulatory and Th17 Cells during Infancy Is Disrupted by HIV Exposure and Gut Epithelial Damage
IF: 5.426 -
Association between glial fibrillary acidic protein, glial-derived neurotrophic factor, and fatty acid-binding protein-2 at birth in the incidence of necrotizing enterocolitis in preterm infants
IF: 3.569Journal： Frontiers in Pediatrics (2022)Reactivity：HumanSample Type：blood -
Dysfunctional oxidative stress response in first-episode of schizophrenia
IF: 0.523Journal： TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH (2022)Reactivity：HumanSample Type：serum -
Intestinal fatty acid-binding protein is a biomarker for diagnosis of biliary tract infection
-
Fontan protein-losing enteropathy is associated with advanced liver disease and a proinflammatory intestinal and systemic state
IF: 5.175 -
Intestinal Permeability in Children with Celiac Disease after the Administration of Oligofructose-Enriched Inulin into a Gluten-Free Diet—Results of a Randomized, Placebo-Controlled, Pilot Trial
IF: 4.546
实验操作视频
